(TEM) Tempus AI, Common Stock - Ratings and Ratios
Diagnostics, Data Platform, Trial Matching, Algorithms, Software
TEM EPS (Earnings per Share)
TEM Revenue
Description: TEM Tempus AI, Common Stock
Tempus AI, Inc. is a healthcare technology company providing cutting-edge diagnostics and data analytics to healthcare providers, pharmaceutical companies, and researchers. Its services include next-generation sequencing diagnostics, molecular genotyping, and anatomic and molecular pathology testing, as well as a suite of analytical services and cloud-based tools.
From a business perspective, Tempus AIs offerings can be broken down into several key areas: Insights, a license library of linked clinical and molecular data; Trials, a clinical trial matching service; Next, a suite of algorithmic tests in oncology; Hub, a platform for ordering and managing tests; and Lens, a platform for researchers to access and analyze Tempus data. The company has also established strategic collaborations, including a partnership with AstraZeneca to develop therapeutic programs in oncology.
To evaluate Tempus AIs performance, key performance indicators (KPIs) such as revenue growth, customer acquisition cost, and customer retention rate can be used. Additionally, metrics such as the number of tests performed, the number of patients enrolled in clinical trials, and the number of pharmaceutical company partnerships can provide insight into the companys operational performance. The companys ability to expand its data library and improve its analytical services will be crucial in driving future growth.
From a financial perspective, Tempus AIs market capitalization is approximately $10.55 billion, indicating a significant presence in the market. However, the companys negative return on equity (-530.65%) suggests that it is currently operating at a loss. As the company continues to invest in its business, monitoring its burn rate, cash reserves, and path to profitability will be essential. Key financial metrics to watch include revenue growth, gross margin, and operating expenses as a percentage of revenue.
TEM Stock Overview
| Market Cap in USD | 13,572m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2024-06-14 |
TEM Stock Ratings
| Growth Rating | 79.2% |
| Fundamental | 33.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 31.0% |
| Analyst Rating | 3.83 of 5 |
TEM Dividends
Currently no dividends paidTEM Growth Ratios
| Growth Correlation 3m | 58.6% |
| Growth Correlation 12m | 56.2% |
| Growth Correlation 5y | 63.3% |
| CAGR 5y | 83.13% |
| CAGR/Max DD 3y | 1.41 |
| CAGR/Mean DD 3y | 2.74 |
| Sharpe Ratio 12m | 0.75 |
| Alpha | 62.88 |
| Beta | 0.972 |
| Volatility | 65.34% |
| Current Volume | 5151.8k |
| Average Volume 20d | 9002.1k |
| Stop Loss | 79.1 (-7.1%) |
| Signal | -0.44 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-199.7m TTM) > 0 and > 6% of Revenue (6% = 57.1m TTM) |
| FCFTA -0.13 (>2.0%) and ΔFCFTA 15.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.74% (prev 82.24%; Δ -58.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -52.0m > Net Income -199.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (173.4m) change vs 12m ago 12.46% (target <= -2.0% for YES) |
| Gross Margin 62.49% (prev 50.84%; Δ 11.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 76.47% (prev 68.88%; Δ 7.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.62 (EBITDA TTM -174.2m / Interest Expense TTM 66.7m) >= 6 (WARN >= 3) |
Altman Z'' -6.73
| (A) 0.14 = (Total Current Assets 644.2m - Total Current Liabilities 418.2m) / Total Assets 1.63b |
| (B) -1.39 = Retained Earnings (Balance) -2.26b / Total Assets 1.63b |
| warn (B) unusual magnitude: -1.39 — check mapping/units |
| (C) -0.19 = EBIT TTM -241.5m / Avg Total Assets 1.24b |
| (D) -1.71 = Book Value of Equity -2.25b / Total Liabilities 1.32b |
| Total Rating: -6.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.26
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -1.50% = -0.75 |
| 3. FCF Margin -22.18% = -7.50 |
| 4. Debt/Equity 2.61 = -0.17 |
| 5. Debt/Ebitda -4.63 = -2.50 |
| 6. ROIC - WACC -39.19% = -12.50 |
| 7. RoE -107.1% = -2.50 |
| 8. Rev. Trend 96.83% = 7.26 |
| 9. EPS Trend 78.24% = 3.91 |
What is the price of TEM shares?
Over the past week, the price has changed by +6.12%, over one month by +15.38%, over three months by +18.24% and over the past year by +55.72%.
Is Tempus AI, Common Stock a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TEM is around 90.04 USD . This means that TEM is currently overvalued and has a potential downside of 5.77%.
Is TEM a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 72.7 | -14.6% |
| Analysts Target Price | 72.7 | -14.6% |
| ValueRay Target Price | 101 | 18.7% |
Last update: 2025-09-06 04:49
TEM Fundamental Data Overview
CCE Cash And Equivalents = 291.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 36.3349
P/S = 14.2562
P/B = 42.8115
Beta = None
Revenue TTM = 952.0m USD
EBIT TTM = -241.5m USD
EBITDA TTM = -174.2m USD
Long Term Debt = 798.0m USD (from longTermDebt, last quarter)
Short Term Debt = 9.38m USD (from shortTermDebt, last quarter)
Debt = 807.4m USD (Calculated: Short Term 9.38m + Long Term 798.0m)
Net Debt = 666.9m USD (from netDebt column, last quarter)
Enterprise Value = 14.09b USD (13.57b + Debt 807.4m - CCE 291.3m)
Interest Coverage Ratio = -3.62 (Ebit TTM -241.5m / Interest Expense TTM 66.7m)
FCF Yield = -1.50% (FCF TTM -211.2m / Enterprise Value 14.09b)
FCF Margin = -22.18% (FCF TTM -211.2m / Revenue TTM 952.0m)
Net Margin = -20.98% (Net Income TTM -199.7m / Revenue TTM 952.0m)
Gross Margin = 62.49% ((Revenue TTM 952.0m - Cost of Revenue TTM 357.1m) / Revenue TTM)
Tobins Q-Ratio = -6.25 (set to none) (Enterprise Value 14.09b / Book Value Of Equity -2.25b)
Interest Expense / Debt = 2.67% (Interest Expense 21.6m / Debt 807.4m)
Taxrate = 21.0% (US default)
NOPAT = -241.5m (EBIT -241.5m, no tax applied on loss)
Current Ratio = 1.54 (Total Current Assets 644.2m / Total Current Liabilities 418.2m)
Debt / Equity = 2.61 (Debt 807.4m / last Quarter total Stockholder Equity 309.6m)
Debt / EBITDA = -4.63 (Net Debt 666.9m / EBITDA -174.2m)
Debt / FCF = -3.82 (Debt 807.4m / FCF TTM -211.2m)
Total Stockholder Equity = 186.5m (last 4 quarters mean)
RoA = -12.29% (Net Income -199.7m, Total Assets 1.63b )
RoE = -107.1% (Net Income TTM -199.7m / Total Stockholder Equity 186.5m)
RoCE = -24.53% (Ebit -241.5m / (Equity 186.5m + L.T.Debt 798.0m))
RoIC = -30.01% (NOPAT -241.5m / Invested Capital 804.8m)
WACC = 9.18% (E(13.57b)/V(14.38b) * Re(9.60%)) + (D(807.4m)/V(14.38b) * Rd(2.67%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -37.11 | Cagr: 0.19%
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -211.2m)
EPS Correlation: 78.24 | EPS CAGR: 0.0% | SUE: 0.07 | # QB: False
Revenue Correlation: 96.83 | Revenue CAGR: 69.84%
Additional Sources for TEM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle